Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunity and Reinfection
Open Access
- 2 January 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 73 (9), e2992-e2994
- https://doi.org/10.1093/cid/ciaa1936
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- An mRNA Vaccine against SARS-CoV-2-Preliminary ReportThe New England Journal of Medicine, 2020
- Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humansScience, 2020
- Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 VirusCell, 2020
- The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patientsScience Immunology, 2020
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020
- mRNA vaccine delivery using lipid nanoparticlesTherapeutic Delivery, 2016
- Duration of Antibody Responses after Severe Acute Respiratory SyndromeEmerging Infectious Diseases, 2007
- Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with PseudotypesEmerging Infectious Diseases, 2005
- Lung mucosal immunity: immunoglobulin‐A revisitedEuropean Respiratory Journal, 2002
- The time course of the immune response to experimental coronavirus infection of manEpidemiology and Infection, 1990